ATXN2. They also provide extremely convincing evidence for a major role of C9ORF72 complex in autophagy and provide a molecular explanation for the known genetic interaction between C9ORF72 and ATXN2. Summarizing, this is a seminal study of the highest importance.
There are some points that could be clarified to improve the readibility and impact of the paper. Also, a few control experiments could be performed, if technically doable.
Major comments: 1) the authors used an expression vector with optimized sequence for C9ORF72. This is only mentioned in the materials and methods, and might explain, eg by modifying translation efficacy, some dyscrepancies with the Farg et al study. It would be helpful that this is mentioned in the result section, and, if relevant, that these potential differences with the Farg et al paper are discussed in depth in the discussion (and not in the result section). In general, a side-by-side comparison of this study with the Farg study would be useful to clarify the literature.
2) The mass spectrometry results of proteins interacting with C9ORF72 are impressive: the authors identified as C9ORF72 interactors a large number of proteins previously genetically associated with ALS, including senataxin (ALS4), TDP-43, P62 (SQSTM1), TBK1 but also dynactin and dynein subunits that were associated with SBMA and CMT diseases. This is a potential major discovery of a protein complex directly related with ALS that is further strengthened by their demonstration of TBK1 mediated phosphorylation of C9ORF72 complex and interaction with optineurin. This should be highlighted in the manuscript. Could the authors perform a gene ontology analysis to determine whether GO terms related with neurodegenerative diseases (and ALS in particular) are enriched in this list of interacting proteins?
3) The identification of TDP-43 as a potential interacting partner of C9ORF72 (supplementary table 1) is extremely interesting and surprinsingly not discussed by the authors. The manuscript would gain of substantiating this protein interaction, if validated by an independent technique such as co-IP. This is of special interest considering the effects of C9ORF72 knockdown on TDP43 ( Figure  3F ). 4) The authors should clarify whether or not WDR41 was included in experiments of Figure 1D . They show that the C9ORF72 complex is composed of C9ORF72, WDR41 and SMCR8 in Figure  1A -C but figure 1D only includes C9ORF72 and SMCR8 as expression vectors. Could the authors explain why they did not include WDR41 in these experiments? Whether this was for technical reasons, this should be discussed. 5) Validation of shRNA mediated knockdown of C9ORF72 in mouse cells (at least on cell lines, Figure 3 and 4A) and in zebrafish (Figure 4 ) could be useful. It is known that morpholino-mediated knock-down does not always lead to decreased mRNA, and that C9ORF72 antibodies are unfortunately mostly useless to measure endogenous levels of C9ORF72. If such experiments are not technically doable, then, the limitations in their interpretation should be clearly disclosed. 6) Is it possible that the different phenotypes observed for the two ATXN2 variants are caused by different expression levels of the transfected proteins? Here again, a RT-qPCR or western validation of the transgene expressions would be interesting.
Minor comments 1) The title of the paper is somewhat difficult to read with its double negation (decreased... impairs...). In reviewer's opinion, the authors could claim that C9ORF72 is required for autophagy and mitigates toxicity of mid sized ATXN2 repeats.
2) The abstract of the paper would also require editing as it does not mention that C9ORF72 mutation leads to haploinsufficiency, nor justifies the relevance of autophagy and intermediate size ATXN2 repeats to ALS/FTD. 3) it is not precised whether the expression vectors used are human or mouse. 4) In all figures involving co-IP (1B, 1D, 2A, 3A, 3B), the antibody used for immunoblot after IP should be mentioned on the corresponding panels. Also, include MWM according to EMBO J guidelines. 5) The differences between this study and Farg study should be presented in the discussion (and not in the result section (page 10). 6) There are several typographical errors throughout the manuscript: a. Page 3: "are now considered" and not "consider" b. The sentence beginning with "a notion emphasized..." has no verb. c. Page 5: "prone to aggregation" and not "prone of aggregation" d. Page 7: "mutated" or "mutant" and not "muted" e. Page 7: "GDP-bound" and not "GDT-bound" f. " Figure" and not "figures" at several occasions (eg page 7: supplementary figures 1D, but also on second to last line of page 7, and several times on page 8) g. page 8: "C9ORF72 forms a specific complex" and not "form" h. page 9: co-immunoprecipitation is mispelled twice on this page i. page 12: "induced significant cell death" and not "induce" j. page 15: "we did not test" and not "tested" k. figure 1: "light chain" and not "ligth" Referee #3:
This paper describes the discovery of C9ORF72 binding partners that appear to converge on a network of macroautophagy related proteins. The authors bring credence to this idea by showing that C9ORF72 is phosphorylated by TBK1 and also by ULK1 and they go on to show that C9ORF72 is needed for the initiation of macroautophagy in cells. The authors go on to provide evidence that the consequence of C9ORF72-autophagy defects is that proteins prone to aggregation accumulate. However, there seems to be a strange specificity to this process because TDP43 and ATXNQ30x accumulate in cells and ATXNQ30x also in zebrafish, but several other aggregation prone proteins do not. I think there are interesting aspects to the paper: the finding that C9ORF72 binds to a number of proteins involved in autophagy and the finding that the protein may be involved in the process. However, while the biochemistry that identifies protein interacting partners is solid (figure 1), everything that follows is much weaker and rather superficial. In my mind, an EMBOj paper digs deeper and fleshes out the mechanism following an initial observation in much more detail. This is a missed opportunity and I do not think the paper as it stands is a good candidate for EMBOj.
-the data concerning the identification of interactors of C9ORF72 are solid in vitro, however we do not know if these interactions occur in vivo, nor if the relevant proteins are co expressed or present in the same subcellular compartments. Similarly, C9ORF72 is implicated in autophagy in this study but it is not known if the protein is present on autophagosomes.
-The mechanistic data are very superficial: (a) it is shown that the C9ORF72 complex harbors GEF activity towards specific Rabs. What are the cellular consequences of this activity? Is this relevant in vivo? (b) it is shown that C9ORF72 is phosphorylated by kinases in autophagy. Does this affect GEF activity? Is this relevant for autophagy in cells and in vivo? These are very obvious questions that are very relevant but have not been looked at.
-How is C9ORF72 regulating autophagy? The data are very descriptive and a mechanism of how this protein may be acting is not proposed nor tested.
-loss of C9ORF72 blocks LC3 vesicle formation and thus macroautophagy. Is this also true in zebrafish neurons? If so, what is the mechanism behind the observed specificity of C9ORF72 towards ATXNQ30x (and likely TDP43) and not other aggregation prone proteins that are presumably also targeted by macroautophagy? -several controls are lacking such as an evaluation of knock down efficiency in the shRNA/morpholino experiments. The effect on viability of fish when expressing other aggregationprone proteins like SOD1, FUS, HTT etc while knocking down C9ORF72? The effect of inhibiting autophagy independently of C9ORF72: are the same defects observed? Knocking down the other binding partners in the C9ORF72 complex etc etc...
-the differences compared to previously published work (ie the types of Rabs that C9ORF72 binds to and the fact that C9ORF72 loss of function was previously shown to result in an INCREASE in the autophagic marker LC3BII -Farg et al) are inadequately explained. As suggested by all three referees, we tried immunoprecipitation of endogenous C9ORF72 with commercial antibodies (we tested Abcam Ab121779, Ab183892, Ab171428; Santacruz S-14; Euromedex GTX119776; Proteintech 66140-1-AP and 22637-1-AP) from adult wild type mouse brain. We detected pull-down of endogenous Smcr8, hence confirming interaction between endogenous C9ORF72 and Smcr8. However, specificity and sensitivity of these commercial antibodies were very poor and immunoprecipitates had a number of non-specific proteins. Thus, we developed our own monoclonal antibodies. To make a long story short, we failed to obtain specific antibodies against C9ORF72 (using either peptides or recombinant C9ORF72 isolated from bacteria, from baculovirus-infected insect cells or from transfected HEK393 cells, etc.). However, we did obtain good and specific antibodies against SMCR8. Thus, we carried immunoprecipitation of endogenous Smcr8 from mouse brain and do confirm interaction with endogenous C9orf72, Wdr41 as well with Rab8a and Rab39b. In contrast, we did not observe interaction with Rab5 or Rab7. These novel data confirm our previous immunopreciptations done in transfected cells and are presented in figure 1E .
C9ORF72 depletion experiment should include a control experiment in which an shRNAinsensitive C9ORF72 expression vector is used to rescue the effects of C9ORF72 depletion. This is very important to show the observed cellular phenotypes are indeed due to loss of C9ORF72.
This is indeed an important control that was missing from our previous draft. These novel data are now included as Supplementary figure 2G. Overall, we observed that expression of a siRNAresistant C9ORF72 (long isoform) fully rescued the accumulation of P62 induced by siRNAmediated depletion of C9orf72 in neuronal GT1-7 cells. In contrast, expression of the short form of C9ORF72 (also resistant to siRNA) did not correct autophagy alteration due to loss of C9orf72.
Again, the authors reported that "depletion of C9ORF72 leads to accumulation of TDP-43 and p62-positive protein aggregates," which seems to contradict with the conclusion that loss of function of C9ORF72 is not deleterious by itself. To resolve this issue, the control experiment suggested above is very important. Moreover, C9ORF72 KO mice have been generated in several labs. The authors should look into these mice and see whether there is an autophagy phenotype.
This is an excellent suggestion and we are in the process of developing trigenic LoxP-C9orf72 knockout x Nestin-CRE x Atxn2 polyglutamines knockin mice to test any potential neuronal degeneration as well as autophagy alteration demonstrating synergy between loss of C9ORF72 and ATXN2 with intermediate polyQ size. However, development of murine models is time consuming and way beyond the scope and time frame of this work.
The authors observed little toxicity and no abnormal motor phenotype associated with a reduction of C9orf72 in fish. The difference between this experiment and cell culture studies presented earlier (as well as a published studying showing an opposite effect of loss of C9ORF72 on autophagy) should be explained.
This difference between our work and the study of Ciura and collaborators simply originate from the fact that we used 50% of the dose of antisense oligonucleotide morpholino used previously (Ciura et al., 2013) . In these conditions, we observed a partial depletion (~50%) of C9orf72 expression (as observed in ALS-FTD patients) and no obvious pathogenic effect alone, while it is deleterious in presence of ATXN2 with intermediate polyQ size. This is now clarified.
Concerning the differences between our study and the work of Farg and colleagues (Farg et al., 2013), these are probably inherent to the different approaches, material and methods used. Indeed, we studied C9ORF72 in complex with SMCR8, while Farg and colleagues studied it alone. Similarly, we developed our own monoclonal antibody for immunoprecipitation since we found that commercial antibodies present little specificity. Also, immunoprecipitation in the work of Farg and colleagues were performed in 50 mM Tris but without NaCl or KCl, while we used 50 mM Tris + 150 mM NaCl. Difference in salt concentration may change specificity of protein-protein interactions. Finally, in absence of analysis of autophagy flux in the work of Farg and colleagues it is difficult to interpret their observed increase of LC3B-II. Indeed, an increase of LC3B-II could reveal either enhanced autophagy activity, or in contrast, a inhibition of autophagy resolution by the lysosome. This is now debated in the discussion.
In the last sentence of Page 3, C9orf2 should be C9orf72.
Thanks! This is now corrected. . Also, we hope to have cover most of the publications related to our work, but we are open to any suggestion if the Referees consider that some references are missing.
In the Results section, each subtitle is followed by a single long paragraph. It would help if the authors could break them up into shorter paragraphs, so that it is easier for readers to follow the flow of different experiments.
This is now corrected, and indeed the text is now much easier to read and to apprehend.
According to the guidelines for autophagy study (Klionsky et al., Autophagy 2012), one should compare the relative ratios of LC3-II to actin in control and C9ORF72 depleted cells.
Novel western blot panels against Actin demonstrating equal loading are now included in Figure 2B and Supplementary 2E.
REFEREE #2:
The manuscript by Sellier Also, we analyzed the difference between our work and the study of Farg and collaborators in the discussion. However, please note that these two studies are different in their approaches (C9ORF72 alone in Farg et al, C9ORF72 in complex in our work), methods (no salt in immunoprecipitation wash buffer in Farg et al., etc.) and materials (commercial versus in-house generated antibodies, different cells, etc.), thus any direct comparison or criticism is rather difficult.
2) The mass spectrometry results of proteins interacting with C9ORF72 are impressive: the authors identified as C9ORF72 interactors a large number of proteins previously genetically associated with ALS, including senataxin (ALS4), TDP-43, P62 (SQSTM1), TBK1 but also dynactin and dynein subunits that were associated with SBMA and CMT diseases. This is a potential major discovery of a protein complex directly related with ALS that is further strengthened by their demonstration of TBK1 mediated phosphorylation of C9ORF72 complex and interaction with optineurin. This should be highlighted in the manuscript. Could the authors perform a gene ontology analysis to determine whether GO terms related with neurodegenerative diseases (and ALS in particular) are enriched in this list of interacting proteins?
We would like to thank the Reviewer for this helpful suggestion. Indeed, bioinformatics analysis of the C9ORF72 interactome using the DAVID database predicted a potential association with ALS disease. Further analyzes for KEGG, GO and Reactome biological pathways revealed significant enrichment for autophagy and protein degradation pathways, but also for adaptive immune system and activation of the NFKB pathway. While a link with autophagy would fit with our present data, a connection with the immune system and NFKB pathway was less expected, but may be of interest considering the importance of TBK1 and RAB8 for adaptive immunity. These predictions are now added in the result section. Figure  3F ). We tested binding of C9ORF72 to TDP-43 by co-immunoprecipitation, but found no detectable interaction. We believe that TDP-43 found by proteomic is either a false positive or a weak and indirect interactant of C9ORF72. It is also highly possible that TDP-43 appears in C9ORF72 interactome as a "client" of autophagy regulated by C9ORF72. The absence of coimmunoprecipitation between C9RF72 and TDP-43 is now clarified in the text. Figure 1D . Figure  1A -C but figure 1D 
3) The identification of TDP-43 as a potential interacting partner of C9ORF72 (supplementary table 1) is extremely interesting and surprinsingly not discussed by the authors. The manuscript would gain of substantiating this protein interaction, if validated by an independent technique such as co-IP. This is of special interest considering the effects of C9ORF72 knockdown on TDP43 (

4) The authors should clarify whether or not WDR41 was included in experiments of
They show that the C9ORF72 complex is composed of C9ORF72, WDR41 and SMCR8 in
only includes C9ORF72 and SMCR8 as expression vectors. Could the authors explain why they did not include WDR41 in these experiments? Whether this was for technical reasons, this should be discussed.
Indeed, it was for technical reason since addition of WDR41 in the co-transfection mix reduces or even abolishes expression of some Rab GTPases. This is probably caused by transcription interference due to too many plasmids (Rab GTPase, C9ORF72, SMCR8 and WDR41) being expressed at the same time. This is now explained in the text and co-immunoprecipitations of SMCR8, C9ORF72 and WDR41 with RAB8A and RAB39B are now presented in the supplementary figure 1D. Figure 3 and 4A) and in zebrafish (Figure 4) Indeed, commercial antibodies are rather of poor quality, at least in our hand. Thus, we added in figure 2B, supplementary figure 2E and supplementary figure 5E quantitative RT-qPCR confirming previous immunoblotting data of reduced expression of C9orf72 mRNA expression upon shRNA, siRNA or AMO treatment.
5) Validation of shRNA mediated knockdown of C9ORF72 in mouse cells (at least on cell lines,
6) Is it possible that the different phenotypes observed for the two ATXN2 variants are caused by different expression levels of the transfected proteins? Here again, a RT-qPCR or western validation of the transgene expressions would be interesting.
Immunoblotting or RT-qPCR demonstrating equal expression of ATXN2 Q22x or ATXN2 Q30x upon C9ORF72 knockdown compared to control conditions are now presented in supplementary figures 5B, 5C and 5F for both in vitro and in vivo conditions. Of interest and as reported previously (Elden et al., 2010), ATXN2 with intermediate size of polyQ is expressed at higher levels than ATXN2 with control size of polyQ (compare panels B and C of the supplementary figure 5). Thus, it is possible that the toxicity of ATXN2 with intermediate polyQ is due to its higher expression and that ATXN2 with normal size would also be toxic, but upon a much longer time period (hence, undetectable in our time-restricted cell or zebrafish models). This possibility is now debated in the discussion.
Minor comments
1) The title of the paper is somewhat difficult to read with its double negation (decreased... impairs...). In reviewer's opinion, the authors could claim that C9ORF72 is required for autophagy and mitigates toxicity of mid sized ATXN2 repeats.
This would be indeed a much better tittle. However, we did not demonstrate that over-expression of C9ORF72 mitigates toxicity of ATXN2 with intermediate polyQ size (we observed no toxicity of ATXN2 Q30x, hence did not test its rescue by C9). In short, the double negation is inelegant and confusing but faithfully reflects our experiments.
2) The abstract of the paper would also require editing as it does not mention that C9ORF72 mutation leads to haploinsufficiency, nor justifies the relevance of autophagy and intermediate size ATXN2 repeats to ALS/FTD.
These informations were indeed missing, and the abstract is now clarified.
3) It is not precise whether the expression vectors used are human or mouse.
All expression vectors correspond to the human cDNAs. This is now clarified in the Material & Methods section. Also, human mRNAs or proteins are now indicated in upper cases throughout the text, while endogenous mouse genes or proteins are signaled in lower cases. (1B, 1D, 2A, 3A, 3B) , the antibody used for immunoblot after IP should be mentioned on the corresponding panels. Also, include MWM according to EMBO J guidelines. Antibodies used for immunoblotting and imunoprecipitations, as well as molecular weights are now included in all figure panels.
4) In all figures involving co-IP
5) The differences between this study and Farg study should be presented in the discussion (and not in the result section (page 10).
Indeed, our study differs from the work of Farg and collaborators on two points. First, we found that the C9ORF72 complex interacts with RAB8 and RAB39, but not with RAB7, RAB5 or RAB11. Second, we found a partial effect of C9orf72 loss on autophagy detected only when we investigated autophagy flux, while Farg and collaborators observe an effect on basal condition. Also, Farg and colleagues observed an increase of LC3B-II, but without analysis of autophagy flux, this can be interpreted either as activation or inhibition of autophagy. This is now debated in the discussion. However, please note that these two studies are different in their approaches (C9ORF72 alone in Farg et al, C9ORF72 in complex in ours), methods (different composition of immunoprecipitation buffer, etc.) and materials (commercial versus home made antibodies, different cells, etc.). Thus any direct comparison or criticism is difficult. We would like to thank the Reviewer for this thorough read. These typos have been now corrected.
REFEREE #3:
This paper describes the discovery of C9ORF72 binding partners that appear to converge on a network of macroautophagy related proteins. The authors bring credence to this idea by showing that C9ORF72 is phosphorylated by TBK1 and also by ULK1 and they go on to show that C9ORF72 is needed for the initiation of macroautophagy in cells. The authors go on to provide evidence that the consequence of C9ORF72-autophagy defects is that proteins prone to aggregation accumulate. However, there seems to be a strange specificity to this process because TDP43 and ATXNQ30x accumulate in cells and ATXNQ30x also in zebrafish, but several other aggregation prone proteins do not. These are indeed important questions. Thus, we tested whether a constitutively active GTP locked RA39b mutant, which does not require GEF activity, could rescue absence of C9orf72, and indeed, GTP-locked RAB39b corrected autophagy alteration due to siRNA-depletion of C9orf72 in neuronal cells. As control, GDP-locked RAB39b had no rescue effect. These novel results presented as figure  2D suggest that the GEF activity of C9ORF72 is important for RAB39b to promote autophagy.
I think there are interesting aspects to the paper: the finding that C9ORF72 binds to a number of proteins involved in autophagy and the finding that the protein may be involved in the process. However, while the biochemistry that identifies protein interacting partners is solid (figure 1), everything that follows is much weaker and rather superficial. In my mind, an EMBOj paper digs deeper and fleshes out the mechanism following an initial observation in much more detail. This is a missed opportunity and I do not think the paper as it stands is a good candidate for
Similarly, we constructed a mutant of SMCR8 that mimics a constitutive phosphorylation by the TBK1 kinase. Significantly, expression of that phosphomimic mutant rescue autophagy alteration caused by siRNA-depletion of Smcr8, while a phospho-dead mutant (serine 402 and threonine 796 changed in alanine) had no rescue activity, demonstrating that phosphorylation of SMCR8 by TBK1 is indeed crucial to SMCR8 activity (results included as a novel figure 3D) . As further control, a mutant of SMCR8 that mimics constitutive phosphorylation by ULK1 had no rescue activity. Finally, we also observed correction of autophagy alteration due to siRNA-mediated depletion of TBK1 by either mutant SMCR8 that mimics constitutive TBK1 phosphorylation, or by constitutively active GTP-locked RAB39b, hence demonstrating the importance of phosphorylation of SMCR8, but also the crucial role of exchange of GDP/GTP for RAB39b to control autophagy mediated by TBK1. These novel results presented as figure 3E suggest that TBK1, C9ORF72-SMCR8 complex and RAB39b belong to a common pathway regulating autophagy in neurons.
As further control that RAB39B constitutively active is specific to the C9ORF72 pathway, we also tested whether GTP-locked RAB39b would rescue autophagy dysfunction caused by siRNAmediated loss of TDP-43 and observed no rescue (Supplementary figure 4) . These results suggest that TDP-43 and C9ORF72 act on different pathways, or that TDP-43 regulates autophagy downstream of RAB39b.
-How is C9ORF72 regulating autophagy? The data are very descriptive and a mechanism of how this protein may be acting is not proposed nor tested.
According to the novel data described above, we propose a tentative model where TBK1 phosphorylates the C9ORF72/ SMCR8 complex, activating RAB39b that would enhance autophagy. This model is presented as figure 6 . However, this is a partial and incomplete model. Notably, it remains to test whether the phosphorylation of SMCR8 directly enhances the GEF activity of the C9ORF72 complex toward RAB39b. Also, the precise molecular function of RAB39b in autophagy is largely unknown. Thus, we agree with Referee #3 that elucidating RAB39b function in autophagy, which may be related to any step of autophagosome formation, migration or fusion with multivesicular bodies or lysosome or any other pathway related to vesicles trafficking controlling autophagy, is a most crucial and exciting topic, but relatively way beyond the scope and time frame of the present study.
-Loss of C9ORF72 blocks LC3 vesicle formation and thus macroautophagy. Is this also true in zebrafish neurons? If so, what is the mechanism behind the observed specificity of C9ORF72 towards ATXNQ30x (and likely TDP43) and not other aggregation prone proteins that are presumably also targeted by macroautophagy?
We did not succeed in testing LC3B in zebrafish due to technical limitations. For further studies we are now developing transgenic zebrafish expressing GFP-tagged LC3B in subsets of neurons, including motor neurons, to analyze autophagy flux in transgenic animals. However, this is obviously a time consuming project beyond the scope of the present article. Concerning the cause of the specificity of C9ORF72 loss toward ATXN2 with intermediate polyQ size compared to other polyQ-containing proteins. This is a crucial question, but it will take much time and effort to address it since it is directly linked to the larger question of specificity of autophagy pathways in neurons, a most complex topic. We now provide RT-qPCR results in addition to immunoblotting to confirm correct depletion of C9ORF72 expression ( figure 2B, supplementary figure 2E and supplementary figure 5E ). Also, we added novel data in the supplementary figure 5E showing that siRNA-depletion of C9ORF72 partners (SMCR8 or WDR41) as well as Bafilomycin treatment also promote aggregation of ATXN2 with intermediate size of polyQ. Since we observed no effect of C9orf72 depletion on aggregation of other polyQ protein, SOD1 or FUS, we did not investigate these proteins in zebrafish. However, it is possible that a study perform in murine model on a much longer time period or with a more extensive depletion of C9orf72 (we depleted C9ORF72 of ~50% to be comparable to the situation observed in ALS-FTD patients) may reveal aggregation and toxicity of other polyQ containing proteins. This possibility is now included in the discussion.
-
-The differences compared to previously published work (ie the types of Rabs that C9ORF72 binds to and the fact that C9ORF72 loss of function was previously shown to result in an INCREASE in the autophagic marker LC3BII -Farg et al) are inadequately explained.
Differences between our study and the work of Farg and collaborator are now debated in the discussion. Concerning the increase of LC3B-II observed in Farg et al., this could originate from the cell type or the extent of depletion of C9ORF72 that are different between the two studies. Also, in absence of analysis of the autophagy flux in Farg's study, it is difficult to conclude about their result (an increase of LC3B-II can indicate either an inhibition of phagosome degradation or an activation of autophagy).
Overall, we would like to thank all three referees for their helpful comments and suggestions. Thank you for submitting your manuscript to The EMBO Journal. Your study has now been rereviewed by referees #1 and 2 and their comments are provided below.
As you can see both referees appreciate the introduced changes and support publication here. Referee #1 has some remaining issues that can be addressed with appropriate text changes. No new experiments are needed. There is one additional point that I think would be nice to address in the discussion and that is a point raised by referee #3 namely "the mechanism behind the observed specificity of C9ORF72 towards ATXNQ30x and not other aggregation prone proteins". I don't know if you have any specific input on this issue, but might be nice to speculate on this in the discussion. If it becomes too complex also OK to forgo.
That should be all. Let me know if we need to discuss anything further -since it there are just text changes needed it would be nice to get the manuscript back as soon as possible.
REFEREE REPORTS
Referee #1:
The authors have satisfactorily addressed most of my comments, and I support publication of the manuscript in EMBO J after minor revision.
Here are a few minor comments to help further improve the manuscript: 1. Figure 2B shows that C9orf72 KD efficiency is about 75%. Thus, the abstract should be revised to state that "Partial loss of function of C9ORF72 is not deleterious". 2. In the Discussion, it should be made clear that C9ORF72 level is reduced by 50% or less in some ALS/FTD cases. TBK1 mutations cause disease through a haploinsufficiency mechanism. Thus, based on loss-of-function studies in this work, we can only speculate that partial reduction in
